Sculptor Capital’s AstraZeneca AZN Stock Holding History

Sculptor Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-291,900	Closed	-$19.9M	–	360
2017 Q2	$19.9M	Buy	+291,900	New	+$19.1M	0.11%	110

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Sculptor Capital's AZN Position: Q3 2022 in Review

Sculptor Capital sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 33,686 shares — an estimated $4.45M sold.

Sculptor Capital first reported a position in AZN in Q2 2014 and held it in 5 quarters. The position peaked at $55.7M in Q1 2022. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

Sculptor Capital reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
Sculptor Capital sold 33,686 AstraZeneca shares in Q3 2022, an estimated $4.45M.
Sculptor Capital first reported a position in AstraZeneca in Q2 2014 and held it in 5 quarters.
Sculptor Capital's AstraZeneca position peaked at $55.7M in Q1 2022.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Sculptor Capital's 13F filing for Q3 2022, filed 14 Nov 2022.